Yourgene Health appoints Dr John Brown to its Board as Non-Executive Director

– UK, Manchester –  Yourgene Health plc (LON: YGEN), the international molecular diagnostics group which commercialises genetic products and services, today announced the appointment of Dr John Brown CBE to the Board of Directors as a Non-executive Director with immediate effect. Dr Brown will act as the Senior Independent Director on the Board.

Adam Reynolds, Chairman of Yourgene, commented: “We are delighted to welcome John to the Board of Yourgene. John has unrivalled experience in working with publicly listed life sciences businesses and we look forward to drawing on his experience as we drive awareness of Yourgene’s expanded product portfolio across our target markets. John’s skill set and experience is a great strategic fit as Yourgene enters the next phase of its growth journey. We look forward to leveraging the team’s experience and continuing to build a truly international molecular diagnostics business.”

Dr Brown has over 20 years’ capital markets experience in the healthcare and life sciences sector. He is currently a Senior Independent Director of BioCity and Acacia Pharma and is Chairman of Cell Therapy Catapult and Synpromics. Additionally, he has previous significant board experience with roles including Chairman of Axis-Shield, Chairman of BTG, Non-executive Director of Vectura and Chief Executive Officer of Acambis.

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group’s products include non-invasive prenatal tests for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene’s commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. One of the advantages that Ativan from https://mi-aimh.org/ativan-lorazepam-online/ offers to other types of benzodiazepine is that it acts on the emotional elements, eliminating them. Thus, it eliminates the tendency to suffer from disorders based on emotional and psychoreactive stress. This quality makes this medicine especially recommended while accompanying some type of psychological intervention. In addition, it is combined with other psychotropic drugs or antidepressants. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

For more information: https://www.yourgene-health.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.